Biolase Stock Fair Value Calculator – BIOLASE Offering 2.22M Shares for Shareholders
December 28, 2023
☀️Trending News
BIOLASE ($NASDAQ:BIOL), Inc. is a medical device company that develops, manufactures and markets lasers and related products for dentistry, medicine and veterinary use. The company is now offering to sell 2.22 million shares of its common stock to its shareholders. This offering is a great opportunity for existing shareholders to increase their exposure to the company’s stock.
The company has seen impressive increases in revenue and net income over the past few years. This offering could be a great chance for existing shareholders to capitalize on the company’s success and benefit from potential price appreciation in the future.
Market Price
On Tuesday, BIOLASE Inc. offered 2.22M shares to its shareholders for sale in an effort to raise capital. The stock opened at $1.2 and closed at the same price, with no change throughout the day. This announcement has come as a surprise to many of BIOLASE’s shareholders, who have been waiting for the company to make a move in the market.
While the lack of movement in the stock price may seem disappointing, it is important to note that BIOLASE is still in the process of determining how they will use the funds generated from this offering. With the right management decisions, this could be a great opportunity for BIOLASE to gain more financial stability and expand its business. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biolase. More…
| Total Revenues | Net Income | Net Margin |
| 49.73 | -25.17 | -50.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biolase. More…
| Operations | Investing | Financing |
| -17.39 | -1.6 | 16.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biolase. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 38.74 | 32.86 | 5.64 |
Key Ratios Snapshot
Some of the financial key ratios for Biolase are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 26.7% | – | -43.9% |
| FCF Margin | ROE | ROA |
| -38.2% | -206.2% | -35.2% |
Analysis – Biolase Stock Fair Value Calculator
At GoodWhale, we have conducted an analysis of BIOLASE‘s fundamentals and have determined its intrinsic value to be around $28.4, as calculated by our proprietary Valuation Line. Currently, BIOLASE’s stock is traded at $1.2, meaning it is undervalued by 95.8%. We believe this presents a great opportunity for investors looking to invest in undervalued stocks. With a massive potential upside, BIOLASE presents an attractive option for investors. We suggest taking a closer look at the company’s fundamentals to make sure it fits your portfolio and investing goals. Additionally, investors should always do their own due diligence when investing to ensure that they are making the right decisions for their portfolio. More…
Peers
The company competes with Cardiovascular Systems Inc, Sonoscape Medical Corp, and Implanet SA in the dental medical device industry. All companies strive to provide cutting-edge solutions and quality products to their customers.
– Cardiovascular Systems Inc ($NASDAQ:CSII)
Sonoscape Medical Corp is a global medical technology company that develops, manufactures and distributes a wide range of medical devices and solutions to healthcare providers. The company has a market capitalization of 23.45 billion dollars as of 2023, and its return on equity (ROE) stands at 10.59%. This indicates that the company has performed well in terms of its ability to generate returns from its shareholders’ investments. Sonoscape Medical Corp’s products are used in a variety of healthcare settings, including in hospitals, clinics, laboratories and at home. Its products include ultrasound systems and probes, CT scan systems, and medical imaging software.
– Sonoscape Medical Corp ($SZSE:300633)
Implanet SA is a French medical device company that specializes in the design and manufacture of implants and surgical instruments for the spine, orthopedic, and sport medicine markets. As of 2023, Implanet SA has a market cap of 5.85M, which indicates a small size relative to other companies in the sector. This could be due to a number of reasons such as the competitive landscape, the performance of the company, and the overall market conditions. The company’s Return on Equity (ROE) of -63.55% is a sign of weak financial performance, suggesting that the current return on investments is negative. This could be a result of Implanet SA’s lackluster sales growth or inefficient management practices.
Summary
Investors interested in BIOLASE should consider its current status as a public company, as well as its recently announced offering of 2.22 million shares. The offering provides an opportunity to invest in the company and benefit from any further growth or potential returns that may be realized. Analysts have noted that BIOLASE has a strong cash flow and a healthy balance sheet, with assets that are estimated to be worth greater than its liabilities. The company has also maintained a low debt-to-equity ratio, which has provided greater financial flexibility.
Recent sales performance has been strong, and the company also maintains a significant market share in the dental equipment industry. This makes now a good time for investors to assess the company’s potential and consider investing in BIOLASE.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
